Introduction {#sec1-0300060517713517}
============

Stroke is a leading cause of death worldwide.^[@bibr1-0300060517713517]^ Ischemic stroke, which is the most common form, occurs as a result of local cerebral ischemia caused by an obstruction within a brain-supplying blood vessel. Ischemic stroke is a complex disease that involves many risk factors, including genetic variants and environmental factors. The search for the genetic factors that increase ischemic stroke risk may facilitate the development of novel and effective approaches to identify high-risk groups. However, we have identified only a few single nucleotide polymorphisms (SNPs), such as rs5128 in Apolipoprotein C3 (*APOC3*),^[@bibr2-0300060517713517]^ rs266729 in adiponectin (*ADIPOQ*),^[@bibr3-0300060517713517]^ and rs2108622 in cytochrome P450 family 4 subfamily F member 2 (*CYP4F2*),^[@bibr4-0300060517713517]^ that are associated with susceptibility to ischemic stroke in large-scale genome-wide association studies.^[@bibr5-0300060517713517][@bibr6-0300060517713517]--[@bibr7-0300060517713517]^

Dyslipidemia often occurs in patients with ischemic stroke. Lipids and lipoproteins have been traditionally associated with atherosclerosis in carotid arteries, which is the leading cause of ischemic stroke. Atherosclerosis often begins with an endothelial injury that makes the endothelium susceptible to the accumulation of lipids and the deposition of thrombus. The apolipoprotein A1-C3-A5 (*APOA1-C3-A5*) gene cluster on chromosome 11q23 (Apo11q) is among the most well-characterized regions of the human genome because of its dynamic association with plasma lipids and lipoproteins. Moreover, its associated haplotypes are highly informative genetic markers in diseases related to hyperlipidemia. Four promoter SNPs, rs670, rs2854116, rs2854117, and rs662799 in the *APOA1-C3-A5* cluster are strongly associated with dyslipidemia through their influence of triglyceride (TG) and very low-density lipoprotein levels.^[@bibr8-0300060517713517][@bibr9-0300060517713517]--[@bibr10-0300060517713517]^ Because dyslipidemia is an important risk factor for ischemic stroke, the genes involved in dyslipidemia might be candidates for assessing ischemic stroke susceptibility. Although individual genetic variants within the Apo11q gene cluster have been independently associated with ischemic stroke in some studies,^[@bibr11-0300060517713517][@bibr12-0300060517713517]--[@bibr13-0300060517713517]^ researchers drew different conclusions and no studies have been able to establish a direct association between haplotypes and the risk of ischemic stroke. Owing to the functional and positional relevance, it is necessary to examine the entire *APOA1-C3-A5* cluster as a whole.

We performed a hospital-based case--control study of 812 patients with ischemic stroke and 844 control participants. We analyzed the relationship between ischemic stroke and four SNPs (rs670, rs2854116, rs2854117, and rs662799) in the promoter of the *APOA1-C3-A5* cluster in the northern Chinese Han population.

Discussion {#sec2-0300060517713517}
==========

The present study evaluated the association between ischemic stroke risk and four functional polymorphisms within the promoter region of the *APOA1-C3-A5* cluster among a northern Chinese Han sample of 812 ischemic stroke cases and 844 controls. Our findings suggest that the rs670 CT/TT genotypes in *APOA1*, the rs662799 AG/GG genotypes in *APOA5*, and the rs2854116 CC genotype in *APOC3* are associated with an increased risk of ischemic stroke. Furthermore, we identified a significantly increased risk of ischemic stroke among the high-risk haplotypes (C-C-C-A and T-T-C-A) for rs670--rs2854116--rs2854117--rs662799. To the best of our knowledge, this study is the first to describe the role of the *APOA1-C3-A5* cluster promoter SNPs with regard to the prevalence of ischemic stroke. Moreover, it is also the first to conduct a haplotype analysis of the northern Chinese Han population.

Previous studies have demonstrated that the SNPs located in the *APOA1-C3-A5* cluster are associated with metabolic syndrome, insulin resistance, and cardiovascular disease in several ethnic populations. The *APOA1-C3-A5* cluster has also been associated with dyslipidemia in many studies.^[@bibr9-0300060517713517],[@bibr14-0300060517713517][@bibr15-0300060517713517]--[@bibr16-0300060517713517]^ In a Taiwanese population, the haplotype containing the minor alleles of *APOA5* rs662799 and *APOA1* rs670 was more prevalent among cases than controls and was significantly associated with the risk of hypertriglyceridemia,^[@bibr17-0300060517713517]^ whereas *APOA5* rs662799 had a significant and independent effect on serum TG concentrations in a Japanese population.^[@bibr18-0300060517713517]^

Regarding the association of the *APOA1-C3-A4-A5* cluster with metabolic syndrome,^[@bibr19-0300060517713517]^ a previous study showed that participants who carry the minor allele of *APOA1* rs670 had an increased risk of developing metabolic syndrome compared with participants with the GG genotype.^[@bibr8-0300060517713517]^ A meta-analysis found that European and Chinese individuals with the C allele of *APOA5* rs662799 were at a 33% and 40% increased risk of developing metabolic syndrome, respectively. Furthermore, *APOA5* rs662799 was reported to interact with the environmental factors associated with metabolic syndrome.^[@bibr19-0300060517713517][@bibr20-0300060517713517]--[@bibr21-0300060517713517]^

The relationship between *APOC3* promoter polymorphisms and a predisposition to insulin resistance has been underscored in a number of studies that identified variants rs2854116 and rs2854117 as having a greater likelihood of insulin resistance compared with wild-type.^[@bibr22-0300060517713517][@bibr23-0300060517713517][@bibr24-0300060517713517]--[@bibr25-0300060517713517]^ *APOC3* promoter polymorphisms were also associated with coronary artery disease,^[@bibr26-0300060517713517]^ while *APOA1* rs670 is a risk marker for coronary artery disease and myocardial infarction among the Indian^[@bibr27-0300060517713517]^ and Japanese populations,^[@bibr28-0300060517713517]^ respectively. Interestingly, the C allele of *APOA5* rs662799 was previously associated with higher levels of TG and TG/high-density lipoprotein (HDL) cholesterol in coronary heart disease and with higher Gensini scores in women only, indicating some degree of gender specificity in the effect of genetic variation.^[@bibr29-0300060517713517]^ However, little was known about the interactions between *APOA1-C3-A5* polymorphisms and ischemic stroke. Consistent with previous results regarding these functional SNPs, our findings suggest that T allele carriers of *APOA1* (rs670), C allele carriers of *APOC3* (rs2854116), and G allele carriers of *APOA5* (rs662799) are associated with an increased risk of ischemic stroke

The mechanism that underlies the associations between these genetic variants and ischemic stroke is unknown. Functional *APOA1-C3-A5* SNPs mediate the widely replicated associations with hypertriglyceridemia and low HDL cholesterol; these SNPs have been studied extensively because they can alter the nuclear transcription factors that mediate apoprotein formation.^[@bibr9-0300060517713517],[@bibr10-0300060517713517],[@bibr17-0300060517713517],[@bibr30-0300060517713517]^ However, previous reports found that rs662799 had no effect on relative luciferase expression, and no transcriptional factors mapped to this site.^[@bibr31-0300060517713517]^ Cui et al.^[@bibr32-0300060517713517]^ conducted experiments using human lung fibroblasts with a heterozygous genotype (rs2266788 CT) and confirmed the effects of microRNA 3201 binding to the *APOA5* 3′ untranslated region and subsequent APOA5 expression.

Given previous knowledge about high linkage disequilibrium between rs2266788 and rs662799, we suppose that the effect of rs662799 variation on ischemic stroke is likely attributable to rs2266788 as a causal variant. Moreover, an increasing number of studies have demonstrated that *APOA1-C3-A5* haplotypes affect TG and HDL cholesterol because they are in linkage disequilibrium.^[@bibr8-0300060517713517][@bibr9-0300060517713517]--[@bibr10-0300060517713517],[@bibr16-0300060517713517],[@bibr20-0300060517713517],[@bibr33-0300060517713517]^ These findings suggest that some serum lipid parameters are partially influenced by interactions between *ApoA1-C3-A5* haplotypes, and that these features together contribute to increased individual ischemic stroke susceptibility. *APOA1-C3-A5* polymorphisms might enhance the conformation or function of the apoprotein related to hypertriglyceridemia, which might in turn explain why our participants were at a high risk of ischemic stroke if they were carriers of the T allele of *APOA1* (rs670), the T allele of *APOA3* (rs2854116), or the G allele of *APOA5* (rs662799). Ding et al previously analyzed the influence of rs662799 on the serum lipid profile, and reported that it was correlated with TG levels, but not independently related with ischemic stroke risk in the studied Turkish subjects.^[@bibr34-0300060517713517]^ This discrepancy could reflect differences in geographical ethnic groups, genetic backgrounds, diseases, age, sample sizes, study design, or the selection pattern of samples between the two studies.

Our study has some shortcomings that should be recognized. First, its sample size was small, and in the absence of large-scale investigations into the role of *APOA1-C3-A5* in ischemic stroke, it remains unclear whether our findings apply to other ethnic populations. Second, ischemic stroke is a complex disease, and the effects of multiple genes and environmental factors were not evaluated in the present study. Finally, our study should be considered preliminary and the results need to be confirmed in more detailed expression and translational studies.

In summary, we demonstrated that common variants of *APOA1*, *APOC3*, and *APOA5* are associated with ischemic stroke, indicating that *APOA1-C3-A5* variants significantly predict a high ischemic stroke risk. Furthermore, the *APOA1-C3-A5* haplotypes significantly affect the risk of ischemic stroke among the northern Chinese Han population. Variations of these genes may serve as useful genetic markers to diagnose ischemic stroke.

Materials and methods {#sec3-0300060517713517}
=====================

Samples {#sec4-0300060517713517}
-------

We recruited 812 patients with ischemic stroke and 844 healthy controls matched for age and gender. Patient data were collected from the Department of Neurology at the First Affiliated Hospital of China Medical University between June 2014 and December 2015. Individuals ranged in age from 40 to 80 years old. Patients were identified as eligible if they were receiving their first diagnosis of acute ischemic stroke based on a neurological examination and radiological imaging. These diagnoses included the sudden onset of a focal neurological deficit that persisted for more than 24 h with a corresponding infarction on brain imaging (computed tomography \[CT\] or magnetic resonance imaging \[MRI\]). Patients with transient ischemic attack, cerebral embolism, cerebral trauma, cerebrovascular malformations, coagulation disorders, autoimmune diseases, tumors, or chronic infectious diseases were excluded. Cases with renal or liver diseases, hematopathy, occlusive arterial disease, or phlebothrombosis of the limbs were also excluded. The controls were recruited from the Physical Examination Department of the First Affiliated Hospital of China Medical University. None of the controls showed evidence of stroke or other neurological diseases. Control participants with tumors, autoimmune diseases, liver ailments, nephrosis, or hematological diseases were excluded. All participants were of Han ethnicity and lived in Liaoning Province, northern China. Clinical records, including general condition (gender, age, BMI, ethnicity, history of smoking, and alcohol use), past history of diabetes and hypertension, serum TG, total cholesterol, low-density lipoprotein, and HDL, were collected from patients and controls. Brain CT or MRI, echocardiography, carotid ultrasound, transcranial Doppler, and electrocardiogram examinations were also required for all patients. BMI was categorized based on the Asian classification of obesity, such that a BMI \> 22.9 was considered overweight. Hyperlipidemia was defined as a total plasma cholesterol level of 5.72 mmol/L, a plasma TG level of 1.7 mmol/L, or the current use of lipid-lowering drugs. The Institutional Ethical Committee of the First Affiliated Hospital of China Medical University approved this study, and it was conducted according to the Code of Ethics of the World Medical Association (Declaration of Helsinki). Written informed consent was obtained from all participants.

SNP selection {#sec5-0300060517713517}
-------------

Well-studied or functional SNPs were selected based on previous studies that documented associations between SNPs in the Apolipoprotein *APOA1-C3-A5* cluster and dyslipidemia or its components. These SNPs included *APOA1* rs670,^[@bibr8-0300060517713517],[@bibr35-0300060517713517]^ *APOC3* rs2854116,^[@bibr11-0300060517713517],[@bibr36-0300060517713517][@bibr37-0300060517713517]--[@bibr38-0300060517713517]^ *APOC3* rs2854117,^[@bibr36-0300060517713517][@bibr37-0300060517713517]--[@bibr38-0300060517713517]^ and *APOA5* rs662799.^[@bibr8-0300060517713517],[@bibr37-0300060517713517],[@bibr39-0300060517713517]^ The minor allele frequency (MAF) of these four SNPs was \> 0.05 in the Chinese Han population.

DNA extraction and genotyping {#sec6-0300060517713517}
-----------------------------

Genomic DNA was extracted from 200 µL of EDTA-anticoagulated peripheral blood using a DNA Purification Kit (Promega, Madison, WI, USA). DNA purity was measured via spectrophotometry, and DNA samples were stored at −80℃. Genotypes were analyzed using the SNaPshot Multiplex Kit (Applied Biosystems Co., Ltd., Foster City, CA, USA). The sequences of PCR primers are shown in [Table 5](#table5-0300060517713517){ref-type="table"}. SNaPshot reactions were performed in a final volume of 10 µL, including 5 µL of the SNaPshot Multiplex Kit (ABI), 1 µL of primer mix, 2 µL of water, and 2 µL of templates, which consisted of the multiplex PCR products for the different genes. The SNaPshot reaction procedures were as follows: initial denaturation at 96℃ for 1 min, then 28 cycles of denaturation at 96℃ for 10 s, annealing at 55℃ for 5 s, and extension at 60℃ for 30 s. Amplified samples were stored at 4℃. Extension products were purified over a 1-h incubation period with 1 U of shrimp alkaline phosphatase (Takara, Otsu, Shiga, Japan) at 37℃, followed by incubation at 75℃ for 15 min to inactivate the enzyme. Purified products (0.5 µL) were mixed with 9 µL of Hi--Di and 0.5 µL of the Liz120 size standard (Applied Biosystems Co., Ltd.). Samples were incubated at 95℃ for 5 min and then loaded onto an ABI 3130XL DNA sequence detector for capillary electrophoresis. Experimental results were analyzed using GeneMapper 4.0 (Applied Biosystems Co., Ltd.).

Statistical analyses {#sec7-0300060517713517}
--------------------

All statistical analyses were performed using Statistical Product and Service Solutions (SPSS) v20.0 if not otherwise specified. All tests were two-tailed, and significance was defined as P \< 0.05. Pearson's χ^2^-test was used to compare the distribution of demographic variables and to examine the differences in risk factors and genotypes with regard to alleles and haplotypes between cases and controls. For each genotype, HWE was tested with a goodness-of-fit χ^2^-test. An unconditional logistic regression was performed to calculate the ORs and 95% CIs to estimate the association between certain genotypes and ischemic stroke. Given the sample size of 812 cases and 844 controls, assuming a genotypic relative risk for a recessive model of 2, an MAF of 0.2, a 1.88% population prevalence of ischemic stroke, and a Type I error probability of 0.05, we would be unable to reject the null hypothesis that OR = 1 with a power of 88.62%. Based on the observed frequencies of the four SNPs, we used the SHEsis analysis platform to calculate linkage disequilibrium indices (D′ and r^2^) and infer haplotype frequencies.^[@bibr40-0300060517713517],[@bibr41-0300060517713517]^

Results {#sec8-0300060517713517}
=======

We identified 812 patients with ischemic stroke and 844 controls. The general characteristics of these participants are summarized in [Table 1](#table1-0300060517713517){ref-type="table"}. No significant difference was found between controls and patients with regard to age or gender. However, a higher prevalence of conventional risk factors for ischemic stroke, such as body mass index (BMI), diabetes mellitus, hypertension, smoking history, and alcohol use, was observed among patients with ischemic stroke compared with the control group. Table 1.Characteristics and risk factors for stroke.VariableCases n (%)Controls n (%)P-valueAge (years)64.34 ± 8.4463.70 ± 6.680.086Age (≤60/\>60 years)292 (36.0)/520 (64.0)276 (32.7)/568 (67.3)0.163Gender (male/female)447 (55.0)/365 (45.0)448 (53.1)/396 (46.9)0.422BMI (≤22.9/\>22.9)414 (51.0)/398 (49.0)548 (64.9)/296 (35.1)\<0.001Diabetes mellitus218 (26.8)62 (7.3)\<0.001Hypertension494 (60.8)170 (20.1)\<0.001History of smoking282 (34.7)130 (15.4)\<0.001History of alcohol use146 (18.0)94 (11.1)0.005TG (≤1.7/\>1.7)520 (64.0)/292 (36.0)574 (68.0)/270 (32.0)0.088TC (≤5.72/\>5.72)624 (76.8)/188 (23.3)721 (86.8)/112 (13.3)\<0.001LDL (≤3.64/\>3.64)658 (81.0)/154 (19.0)746 (88.4)/98 (11.6)\<0.001[^1]

Genotype and allele frequencies of the four SNPs among patients and controls are shown in [Table 2](#table2-0300060517713517){ref-type="table"}. All allele distributions were consistent with Hardy--Weinberg equilibrium (HWE). Table 2.Allele and genotype frequencies of SNPs among cases and controls and their main effects on stroke risk.SNPCasesPercentageControlsPercentageOR (95% CI)[\*](#table-fn3-0300060517713517){ref-type="table-fn"}P-valuers670 CC (ref)43153.10%46855.50%1.00 (ref)-- CT30637.30%34040.30%1.02 (0.76--1.36)0.890 TT759.20%364.30%0.83 (0.52--1.30)0.410 Dominant model CT + TT vs CC1.10 (0.91--1.33)0.33 Recessive model TT vs CC + CT2.28 (1.52--3.44)\<0.001rs2854116 TT (ref)26332.4%24829.4%1.00 (ref)-- TC37646.3%42650.5%0.83 (0.67--1.04)0.105 CC17321.3%17020.1%0.96 (0.73--1.26)0.768 Dominant model TC + CC vs TT0.86 (0.70--1.06)0.169 Recessive model CC vs TT + TC1.07 (0.84--1.35)0.601rs2854117 CC (ref)26833.00%25630.30%1.00 (ref)-- CT37846.60%41849.50%0.86 (0.63--1.18)0.358 TT17020.40%17020.10%0.93 (0.63--1.37)0.725 Dominant model CT + TT vs CC0.88 (0.72--1.09)0.242 Recessive model TT vs CC + CT1.02 (0.80--1.30)0.882rs662799 AA (ref)39348.40%44853.10%1.00 (ref)-- AG32239.70%34040.30%0.98 (0.73--1.33)0.904 GG9711.90%566.60%0.87 (0.58--1.31)0.507 Dominant model AG + GG vs AA1.21 (0.99--1.46)0.057 Recessive model GG vs AA + AG1.91 (1.35--2.69)\<0.001[^2][^3]

As shown in [Table 2](#table2-0300060517713517){ref-type="table"}, neither the genotype nor the allele frequencies of *APOA1* rs670 differed significantly between patients and controls. However, compared with combined variant genotypes (CT + TT), the rs670 TT genotype significantly increased susceptibility to ischemic stroke under a recessive genetic model (odds ratio \[OR\] = 2.28, 95% confidence interval \[CI\] = 1.52--3.44, P \< 0.001; [Table 2](#table2-0300060517713517){ref-type="table"}). Similar results were also found for the genotypes of *APOA5* rs662799. Under a recessive model, the *APOA5* rs662799 GG genotype was associated with a higher ischemic stroke risk (OR = 1.91 (95% CI = 1.35--2.69, P \< 0.001; [Table 2](#table2-0300060517713517){ref-type="table"}). Analyses of *APOC3* rs2854117 and rs2854117 polymorphisms found no significant associations with ischemic stroke under any of the genetic models ([Table 2](#table2-0300060517713517){ref-type="table"}).

Additional analyses were performed using multiple logistic regression, and more significant results were found after adjusting for confounding factors. Using the lowest-risk genotype (*APOA1* rs670 CC) as a reference, we identified a significantly increased risk for ischemic stroke among the high-risk rs670 genotypes CT and TT (adjusted OR = 1.571, 95% CI = 1.103--2.236, P = 0.003 and adjusted OR = 5.175, 95% CI = 3.042--8.807, P \< 0.001, respectively) ([Table 3](#table3-0300060517713517){ref-type="table"}). The association between an increased risk of ischemic stroke and the homozygous variant *APOA5* rs662799 GG genotype and the heterozygous variant AG was also significant (adjusted OR = 1.435, 95% CI = 1.065--1.934, P = 0.004 for AG and OR = 2.079, 95% CI = 1.311--3.294, P = 0.001 for GG) ([Table 3](#table3-0300060517713517){ref-type="table"}). Compared with the *APOC3* rs2854116 TT homozygote, the CC homozygote was associated with a significantly increased risk of ischemic stroke (adjusted OR = 2.428, 95% CI = 1.033--5.709, P = 0.031) ([Table 3](#table3-0300060517713517){ref-type="table"}) Table 3.Risk factors according to multiple logistic regression.FactorBSEWaldOR (95% CI)[\*](#table-fn5-0300060517713517){ref-type="table-fn"}P-value[\*](#table-fn5-0300060517713517){ref-type="table-fn"}Age0.0330.1250.0721.034 (0.810--1.320)0.789Gender0.0410.1190.1201.042 (0.826--1.316)0.729BMI0.6380.12028.1351.893 (1.495--2.396)\<0.001Diabetes mellitus1.2630.17850.2023.538 (2.494--5.018)\<0.001Hypertension1.7210.123195.2515.589 (4.390--7.114)\<0.001History of smoking0.6910.15121.0361.995 (1.485--2.680)\<0.001History of alcohol use0.1720.1830.8861.188 (0.830--1.701)0.347TG0.5000.1966.4941.648 (1.122--2.421)0.011TC0.6910.17415.7701.995 (1.419--2.806)\<0.001LDL0.5850.16612.3581.995 (1.295--2.486)\<0.001rs670 CT vs CC0.4520.1806.2731.571 (1.103--2.236)0.003 TT vs CC1.6440.27136.7405.175 (3.042--8.807)\<0.001rs2854116 TC vs TT0.1040.2740.1451.110 (0.649--1.898)0.660 CC vs TT0.8870.4364.1382.428 (1.033--5.709)0.031rs2854117 CT vs CC−0.0670.2720.0610.935 (0.549--1.593)0.614 TT vs CC−0.7440.4362.9140.475 (0.202--1.117)0.059rs662799 AG vs AA0.3610.1525.6401.435 (1.065--1.934)0.004 GG vs AA0.7320.2359.6972.079 (1.311--3.294)0.001[^4][^5]

The four SNPs were in linkage disequilibrium in this sample (i.e., D\' \> 0.8 or r2 \> 0.4). Of all possible haplotypes, only six showed a frequency of \>0.03 among both cases and controls, and were included in the haplotype analysis. These six haplotypes represented 96.5% of the chromosomes of the cases and 95.2% of those of the controls. No difference was observed in the overall haplotype distribution between cases and controls. Haplotype analysis revealed that the frequencies of the C-C-T-A and T-T-C-A haplotypes of rs670--rs2854116--rs2854117--rs662799 were significantly higher among patients than controls (OR = 1.340, 95% CI = 1.138--1.579, P \< 0.001 and OR = 1.547, 95% CI = 1.230--1.945, P \< 0.001) ([Table 4](#table4-0300060517713517){ref-type="table"}). Table 4.Haplotype frequencies among cases and controls and their relationship with stroke risk.HaplotypeCases (%)Controls (%)OR (95% CIs)P-valueC-T-C-A464 (27.5)459 (28.3)0.943 (0.809--1.099)0.453C-T-C-G178 (10.6)179 (11.1)0.936 (0.751--1.166)0.554C-C-T-A432 (25.6)328 (20.2)1.340 (1.138--1.579)\<0.001C-C-T-G160 (9.5)145 (8.9)1.056 (0.833--1.337)0.654T-T-C-A209 (12.4)134 (8.3)1.547 (1.230--1.945)\<0.001T-C-T-A91 (5.4)127 (7.8)0.664 (0.503--0.877)0.004[^6] Table 5.Primer sequences (5′--3′).SNPPrimer sequencers670Forward: ACTCATTGCA GCCAGGTGAGGAReverse: AGGACCAGTG AGCAGCAACAGGrs2854116_2854117Forward: ACTCGCCTGC CTGGATTGAAACReverse: GCCCTGAACAC AGCCTGGAGTArs662799Forward: GCAGCCCCTGA AAGCTTCACTAReverse: CTGAGCATTTGG GCTTGCTCTC
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[^1]: Abbreviations: BMI, body mass index; TG, triglyceride; TC, total cholesterol; LDL, low-density lipoprotein

[^2]: Abbreviations: SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval

[^3]: ORs and 95% CIs were calculated via a logistic regression.

[^4]: Abbreviations: BMI, body mass index; TG, triglyceride; TC, total cholesterol; LDL, low-density lipoprotein OR, odds ratio; CIs, confidence intervals

[^5]: ORs and 95% CIs were calculated based on logistic regression and adjusted for age, gender, BMI, diabetes mellitus, hypertension, history of smoking, history of alcohol use, TG, TC, and LDL. Wald is a chi-square value equal to B divided by the square error of the standard error (S.E.). Wald is used to test the B value. It was calculated by SPSS.

[^6]: Abbreviations: OR, odds ratio; CIs, confidence intervals
